Brian Druker
Impact in
- Hematology top 0.01%
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
- Genetics top 0.01%
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
Papers in
- Hematology 437
- Chronic Myeloid Leukemia Treatments 351
- Acute Myeloid Leukemia Research 98
- Genetics 309
- Chronic Lymphocytic Leukemia Research 256
- Myeloproliferative Neoplasms: Diagnosis and Treatment 57
- Co-authors
- Elisabeth Buchdunger (10 shared papers)Nicholas Lydon (9 shared papers)Michael W. Deininger (117 shared papers)Renaud Capdeville (9 shared papers)Moshe Talpaz (19 shared papers)Charles L. Sawyers (16 shared papers)Debra Resta (8 shared papers)Hagop M. Kantarjian (28 shared papers)
- Journals
- Blood (236 papers)Journal of Biological Chemistry (27 papers)Cancer Research (24 papers)Leukemia (23 papers)Journal of Clinical Oncology (16 papers)
- Partner nations
- United StatesSwitzerlandGermany
In The Last Decade
Brian Druker
592 papers receiving 53.6k citations
Brian Druker's Hit Papers
Peers
Comparison fields: 5 of 169
- Hematology 29.2k
- Genetics 18.7k
- Rheumatology 11.4k
- Gastroenterology 4.0k
- Oncology 9.8k
Countries citing papers authored by Brian Druker
This map shows the geographic impact of Brian Druker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian Druker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian Druker more than expected).
Fields of papers citing papers by Brian Druker
This network shows the impact of papers produced by Brian Druker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian Druker. The network helps show where Brian Druker may publish in the future.
Co-authors
The 25 scholars most cited alongside Brian Druker, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 611 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia Hit paper breakdown → | 2001 | 3828 |
| 2 | Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells Hit paper breakdown → | 1996 | 2782 |
| 3 | Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome Hit paper breakdown → | 2001 | 2071 |
| 4 | Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor Hit paper breakdown → | 2003 | 1727 |
| 5 | Effect of the Tyrosine Kinase Inhibitor STI571 in a Patient with a Metastatic Gastrointestinal Stromal Tumor Hit paper breakdown → | 2001 | 1529 |
| 6 | Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia Hit paper breakdown → | 2002 | 1523 |
| 7 | Abl Protein-Tyrosine Kinase Inhibitor STI571 Inhibits In Vitro Signal Transduction Mediated by c-Kit and Platelet-Derived Growth Factor Receptors Hit paper breakdown → | 2000 | 1033 |
| 8 | The development of imatinib as a therapeutic agent for chronic myeloid leukemia Hit paper breakdown → | 2004 | 965 |
| 9 | Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Hit paper breakdown → | 1996 | 878 |
| 10 | Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor Hit paper breakdown → | 2000 | 832 |
| 11 | In vitro Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants Hit paper breakdown → | 2005 | 814 |
| 12 | Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia Hit paper breakdown → | 2017 | 814 |
| 13 | Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy Hit paper breakdown → | 2002 | 679 |
| 14 | Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia Hit paper breakdown → | 2000 | 645 |
| 15 | Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia Hit paper breakdown → | 2009 | 628 |
| 16 | CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability Hit paper breakdown → | 2010 | 592 |
| 17 | Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity Hit paper breakdown → | 2010 | 590 |
| 18 | Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias Hit paper breakdown → | 2012 | 531 |
| 19 | Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study Hit paper breakdown → | 2008 | 493 |
| 20 | Translation of the Philadelphia chromosome into therapy for CML Hit paper breakdown → | 2008 | 482 |
About Brian Druker
Brian Druker is a scholar working on Hematology, Genetics, Rheumatology, Molecular Biology and Oncology, having authored 611 papers that have together received 55.0k indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (351 papers), Chronic Lymphocytic Leukemia Research (256 papers), Eosinophilic Disorders and Syndromes (151 papers), Acute Myeloid Leukemia Research (98 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (57 papers), Acute Lymphoblastic Leukemia research (55 papers), Monoclonal and Polyclonal Antibodies Research (36 papers) and Cytokine Signaling Pathways and Interactions (34 papers). The work is most often cited by research in Hematology (29.2k citations), Genetics (18.7k citations), Rheumatology (11.4k citations), Gastroenterology (4.0k citations) and Oncology (9.8k citations). Brian Druker has collaborated with scholars based in United States, Switzerland and Germany. Frequent co-authors include Elisabeth Buchdunger, Nicholas Lydon, Michael W. Deininger, Renaud Capdeville, Moshe Talpaz, Charles L. Sawyers, Debra Resta, Hagop M. Kantarjian, J. Ford and Sayuri Ohno-Jones. Their work appears in journals such as Blood, Journal of Biological Chemistry, Cancer Research, Leukemia and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.